These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 14756139)

  • 1. 'New' FDA delivers in 2003.
    Schmidt E; Wong R
    Nat Rev Drug Discov; 2003 Dec; 2(12):941-2. PubMed ID: 14756139
    [No Abstract]   [Full Text] [Related]  

  • 2. A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
    McCabe AR
    Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844
    [No Abstract]   [Full Text] [Related]  

  • 3. What ails the FDA?
    Okie S
    N Engl J Med; 2005 Mar; 352(11):1063-6. PubMed ID: 15784660
    [No Abstract]   [Full Text] [Related]  

  • 4. Communicating with the FDA: the "third rail" of a new model for drug development.
    Stanski DR; Orloff JJ
    J Clin Pharmacol; 2008 Feb; 48(2):144-5. PubMed ID: 18199890
    [No Abstract]   [Full Text] [Related]  

  • 5. Paying for drug approvals--who's using whom?
    Avorn J
    N Engl J Med; 2007 Apr; 356(17):1697-700. PubMed ID: 17435083
    [No Abstract]   [Full Text] [Related]  

  • 6. Muddied messages about FDA.
    Miller HI
    Nat Biotechnol; 2003 Jul; 21(7):732-3. PubMed ID: 12833084
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmaceuticals and medical devices: FDA oversight. Issue brief.
    Thomson Reuters/West
    Issue Brief Health Policy Track Serv; 2011 Jan; ():1-39. PubMed ID: 21374841
    [No Abstract]   [Full Text] [Related]  

  • 8. FDA perspectives on supplement use by patients on antithrombotic therapy.
    Kim MJ
    Thromb Res; 2005; 117(1-2):197-200; discussion 201-7. PubMed ID: 16188297
    [No Abstract]   [Full Text] [Related]  

  • 9. FDA perspectives on supplement use by patients on antithrombotic therapy: dietary supplement regulatory overview.
    Woo JJ
    Thromb Res; 2005; 117(1-2):193-6; discussion 201-7. PubMed ID: 16253311
    [No Abstract]   [Full Text] [Related]  

  • 10. Risk versus risk: decision-making dilemmas of drug regulation in the United States and Germany.
    Daemmrich A; Krucken G
    Sci Cult (Lond); 2000 Dec; 9(4):505-34. PubMed ID: 15988846
    [No Abstract]   [Full Text] [Related]  

  • 11. Drug development for neglected diseases - the trouble with FDA review vouchers.
    Kesselheim AS
    N Engl J Med; 2008 Nov; 359(19):1981-3. PubMed ID: 18987367
    [No Abstract]   [Full Text] [Related]  

  • 12. They are from the government and they really are here to help you.
    Woosley RL
    J Clin Pharmacol; 2008 Feb; 48(2):142-3. PubMed ID: 18199889
    [No Abstract]   [Full Text] [Related]  

  • 13. Drug safety reform at the FDA--pendulum swing or systematic improvement?
    McClellan M
    N Engl J Med; 2007 Apr; 356(17):1700-2. PubMed ID: 17435081
    [No Abstract]   [Full Text] [Related]  

  • 14. The need for rules and regulations.
    Helmus MN
    Nat Nanotechnol; 2007 Jun; 2(6):333-4. PubMed ID: 18654297
    [No Abstract]   [Full Text] [Related]  

  • 15. The role of the U.S. Food and Drug Administration review process: clinical trial endpoints in oncology.
    McKee AE; Farrell AT; Pazdur R; Woodcock J
    Oncologist; 2010; 15 Suppl 1():13-8. PubMed ID: 20237212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The challenges of globalization in pharmaceutical law--is an international drug approval system modeled after the European system worth considering?
    Purnhagen KP
    Food Drug Law J; 2008; 63(3):623-45. PubMed ID: 19031663
    [No Abstract]   [Full Text] [Related]  

  • 17. Remarks of the Lead Deputy Commissioner of the Food and Drug Administration.
    Friedman MA
    Food Drug Law J; 1998; 53(1):19-23. PubMed ID: 11795333
    [No Abstract]   [Full Text] [Related]  

  • 18. Drugs and vaccines for the common defense: refining FDA regulation to promote the availability of products to counter biological attacks.
    Javitt GH
    J Contemp Health Law Policy; 2002; 19(1):37-116. PubMed ID: 12733223
    [No Abstract]   [Full Text] [Related]  

  • 19. FDA-VMAC calls for increased regulation of new antimicrobials; animal groups question conclusion.
    Nolen S
    J Am Vet Med Assoc; 1999 Mar; 214(6):767, 772. PubMed ID: 10101403
    [No Abstract]   [Full Text] [Related]  

  • 20. New drug law to speed scientific review.
    Nature; 1992 Oct; 359(6396):563. PubMed ID: 1406977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.